No clear answer
Daclizumab: reduce relapses and new lesions in relapsing and progressive MS
relapsing and progressive MS · T-cell co-stimulation / cytokine targeting
Trials have tried this, but none was a controlled phase 2 or 3 trial with a readable result.
Daclizumab was withdrawn in the EU. A positive trial result does not mean the medicine is available.
- Trials
- 1
- Running now
- 0
- Controlled phase 2/3 trials
- 0
- People in controlled trials
- 0
No controlled trial has reported a result yet.
Other linked trials: 1
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Human genetics
Genes linked to MS that these medicines act on: IL2RA
Trials
Other linked trials: 1
These linked trials do not set the status.
- Zenapax to Treat Multiple SclerosisResult in a paper, not read yet
Phase 2 · 1999 · Not randomised
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-27First listed as No clear answer
Related hypotheses
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error